Epitalon 50 mg

Epitalon 50 mg is a research peptide studied for its effects on telomerase activity, telomere length, and circadian rhythm regulation. It is a synthetic pineal tetrapeptide (Ala-Glu-Asp-Gly) that has never been approved for human use and is sold strictly for laboratory research purposes.

No established human dosage exists. The most commonly cited research protocols derive from Russian clinical work by Khavinson et al., which used 5 to 10 mg per day for 10 to 20 consecutive days. Community protocols extend cycles to 10-20 days and repeat once or twice per year. No regulatory body has established an approved dosage.

Epitalon has no relationship to the hypothalamic-pituitary-gonadal axis and is not part of any post-cycle therapy protocol. Its research focus has been on telomerase and circadian rhythm regulation, not hormonal recovery. PCT compounds such as Clomid and Nolvadex address entirely different biological systems.

Epitalon is a synthetic tetrapeptide that has been shown to activate telomerase in human cell cultures, leading to telomere elongation in a dose-dependent manner. It has also been studied for its ability to restore nocturnal melatonin secretion and normalize circadian rhythm in senescent animal models. A 2025 study confirmed telomerase activation in bovine oocyte models.

No human data exists on the time course of epitalon effects. In cell culture studies, telomere elongation was observed after 4 days of treatment. In animal models, effects on melatonin and cortisol rhythms were observed over treatment periods of days to weeks. No human pharmacokinetic study exists to establish a time course for human use.

There is no single longevity peptide that is universally best, and epitalon's human evidence is limited. A 2026 Dana-Farber review cautioned that there is very little new evidence suggesting epitalon and other unapproved peptides are safe and effective. FDA scientists recommended against adding epitalon to the compounding list, citing a lack of evidence for effectiveness.

Epitalon and DSIP have different mechanisms. Epitalon is a pineal tetrapeptide studied for telomerase activation and circadian rhythm regulation through the melatonin system. DSIP is a nonapeptide studied for delta-wave sleep architecture modulation. Both are research peptides with different evidence bases and proposed applications.

Epitalon and epithalamin are different substances. Epithalamin is a crude extract of bovine pineal glands containing many peptides in batch-variable proportions. Epitalon is the synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) built to capture the active sequence. Almost all the human mortality data cited for "epitalon" was generated with epithalamin, the extract.

No human dosing standards exist for epitalon. The 50 mg vial strength is a research quantity. Vial size reflects the lyophilized powder mass, not a single dose. A 50 mg vial is used for longer cycles or split across multiple research applications. At a published research dose of 5-10 mg per day, the vial provides approximately 5-10 doses.

Epitalon 50 mg is labeled at 50 mg of epitalon per vial. It is supplied as a lyophilized powder in a 2 mL vial, requiring reconstitution before laboratory use.

Yes. A published laboratory report dated March 22, 2024 measured Epitalon 50 mg at 54.46 mg/vial, equivalent to 108.92% of its 50 mg label claim. The batch number for this report was #HDEPT23. The complete report can be viewed in the Lab Reports tab.

This is not known. Telomere shortening is one of the limits on how many times a cell can divide. Cancer cells characteristically reactivate telomerase precisely to escape that limit. A compound whose headline mechanism is activating telomerase is, by construction, pushing on the same lever. FDA made this point explicitly in 2026 and noted that the animal studies used short, intermittent dosing, so nothing in the record tells us what chronic exposure does. No human long-term safety data exists.